Patient selection
cellulitis, allergic reaction, HNC
CELLULITIS, AUTOIMMUNE SKIN DISEASE, SKIN TOXICITY, ALLERGIC REACTION
The design of this study was a randomized controlled trial comparing Sanyrene with control intervention in 102 HNC and BC patients receiving radiation therapy. Patients were consecutively enrolled from June 2020 to July 2021 at department of radiation oncology in Xi’an, China. This study (Trial Registration: ChiCTR2100050910) was approved by the medical ethics committee of the first affiliated hospital of the air force medical university. Patients with age ≥ 18 years, ECOG of 0 or 1 and a pathologic diagnosis of HNC and BC receiving radiotherapy (≥ 50 Gy) were eligible. Exclusion criteria were prior RT to the intended field, palliative RT with dose < 50 Gy, receiving breast conserving surgery in BC patients, receiving anti-EGFR monoclonal antibody in HNC patients, pre-existing grade >1 skin toxicity, cellulitis, autoimmune skin disease or incompletely healed wound at intended site. Patients were also excluded if they had known allergic reaction towards any ingredient of Sanyrene, Vitamin E or hyaluronic acid were not able to consent. Receiving concurrent chemotherapy was not an exclusion criterion.